Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$501.37M-39.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark S. Ordan
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 4,280
- Beta
- 0.61
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.45
Financials
Revenue
$501.37M-39.6%Net Income
$46.99M-39.8%EBITDA
$79.36M-52.8%Free Cash Flow
$112.93M-6.0%EPS (diluted)
$0.59-28.9%Shares Outstanding (diluted)
79.73M-14.9%Operating Expenses
$62.70MCash & Debt
$425.84MReturn of Capital
$83.04MRevenue by Segment (annual)
$1.91BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.91B | $165.39M | $1.94 |
| 2024 | $2.01B | $-99.07M | $-1.19 |
| 2023 | $1.99B | $-60.41M | $-0.73 |
| 2022 | $1.97B | $66.33M | $0.80 |
| 2021 | $1.91B | $130.96M | $1.52 |
| 2020 | $1.73B | $-796.49M | $-9.31 |
| 2019 | $1.78B | $-1.50B | $-17.78 |
| 2018 | $3.65B | $268.63M | $2.95 |
| 2017 | $3.46B | $320.37M | $3.42 |
| 2016 | $3.18B | $324.91M | $3.47 |
| 2015 | $2.78B | $336.32M | $3.59 |
| 2014 | $2.44B | $317.28M | $3.30 |
| 2013 | $2.15B | $280.52M | $2.77 |
| 2012 | $1.82B | $240.91M | $2.41 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MD's reported EPS growth of -1.7% a year over 13 years.
- EPS in 5 years
- $1.78
- Implied price
- $19.58
- Return from $30.22
- -8.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $9.74 — -67.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| -11.7% | -24.8% | -20.9% | -17.6% | -14.8% | -12.4% |
| -6.7% | -20.5% | -16.4% | -13.0% | -10.0% | -7.4% |
| -1.7% | -16.2% | -11.9% | -8.3% | -5.2% | -2.4% |
| 3.3% | -12.0% | -7.4% | -3.6% | -0.4% | 2.5% |
| 8.3% | -7.7% | -3.0% | 1.0% | 4.4% | 7.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (12)
- Newszacks.com·12d ago·Positive
What Makes Pediatrix Medical Group (MD) a Strong Momentum Stock: Buy Now? Does Pediatrix Medical Group (MD) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·16d ago·Positive
Pediatrix Medical Group (MD) Upgraded to Buy: Here's What You Should Know Pediatrix Medical Group (MD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·16d ago·Positive
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
What Pediatrix Medical Group (MD) Said on Its Q3 Earnings Call Pediatrix Medical Group NYSE: MD reported third-quarter 2026 adjusted EBITDA of $85 million, with management saying results exceeded its expectations despite rising costs across healthcare delivery. The company narrowed its full-year adjusted EBITDA outlook to a range of $290 million to $300 million.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Pediatrix Medical Group, Inc. (MD) Q3 2026 Earnings Call Transcript Pediatrix Medical Group, Inc. ( MD ) Q3 2026 Earnings Call October 29, 2026 9:00 AM EDT Company Participants David Haddock - Executive Vice President, General Counsel & Secretary Mark Ordan - CEO & Executive Chairman Kasandra Rossi - Executive VP, Treasurer & CFO Conference Call Participants Matthew Mardula - William Blair & Company L.L.C., Research Division Albert Rice - UBS Investment Bank, Research Division Jack Slevin - Jeff…
View source ↗ - Newszacks.com·24d ago·Positive
Pediatrix Medical Group (MD) Beats Q3 Earnings and Revenue Estimates Pediatrix Medical Group (MD) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.67 per share a year ago.
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2026 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 29, 2026.
View source ↗ - Newszacks.com·44d ago·Positive
Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·61d ago·Positive
Can Pediatrix Sustain Growth Despite Lower Patient Volumes? MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
View source ↗ - Newszacks.com·80d ago·Neutral
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue? Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·94d ago·Positive
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·102d ago·Positive
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $0.61 per share
Typical surprise +18.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$0.72 vs $0.65beat
- Tue, Aug 4$0.63 vs $0.59beat
- Tue, May 5$0.44 vs $0.37beat
- Thu, Feb 19$0.50 vs $0.53miss
- Mon, Nov 3$0.67 vs $0.46beat
- Tue, Aug 5$0.53 vs $0.42beat
Estimates and results for MD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MD officers and directors.
- Bought
- —
- Sold
- $4.0m
0 trades
17 trades
- Weis Shirley Asold
- Ordan Mark Ssold
- Rucker Michael A.sold
- Linynsky Laura Asold
- Ordan Mark Ssold
- Moore Mary Ann Esold
- Swift James Dsold
- Linynsky Laura Asold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (195d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Oct 29, 2018 (3d later)Sell$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
